Cleveland’s Auxilium raises $3.4 million Seed Round to scale biomaterials innovation

Cleveland-based Auxilium Health has closed an oversubscribed $3.4 million seed round to push its Aer™ biomaterial platform toward FDA clearance and first-in-human studies, a year after wrapping its oversubscribed pre-seed raise.

Why it matters

For nearly four decades, surgeons and biomaterials researchers have talked about the “race for the surface” — the critical window when a patient’s healing cells and bacteria compete to colonize an implant or wound site.

Most traditional biomaterials try to kill bacteria after they arrive, often leaning on antibiotics and antimicrobial coatings, with mixed results and resistance concerns. Auxilium’s Aer™ platform re-engineers the problem structurally: it mimics the body’s extracellular matrix, is built to resist bacterial attachment from the outset, and is designed to welcome regenerative cells without relying on antibiotics.

By the numbers

• $3.4 million: Total raised in the oversubscribed seed round.
• 12 months: Time elapsed since Auxilium closed its oversubscribed $1.5 million pre-seed round.
• 2x: The new funding more than doubles the company’s prior capital raised.
• 100%: Auxilium’s full-time team has doubled over the last year, attracting top scientists and researchers to relocate to Northeast Ohio.

The Ohio footprint

Headquartered at the Cleveland Clinic’s Global Innovation Center, Auxilium is anchoring a growing biomaterials and medtech cluster in Northeast Ohio. The company operates inside a dense regional support network, backed by the National Science Foundation, the Ohio Department of Development, and the Polymer Industry Cluster — tying its growth to both state development priorities and Ohio’s legacy in polymers and advanced materials.

“Last year, the question was whether the science was real. This year, it’s how fast we can get it to patients,” said Isaiah Kaiser, PhD, founder and CEO of Auxilium Health. “We’re grateful to our investors and partners who believe in the science and the team behind what we’re building. Their confidence lets us move with the urgency this problem deserves.”

What’s next

Auxilium plans to deploy the new capital to advance its lead Aer™-based product through FDA pathways and into first-in-human studies, while expanding its core research and development team. The company’s platform spans wound repair, bone regeneration, and localized delivery, with its initial focus on wound care and infection risk — positioning Aer™ as a modular technology that could scale across multiple surgical and regenerative medicine applications.